News-Medical.Net Urinary Tract Infection News Feed
Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint
Thu, 01 Nov 2018 03:46:24 -0500
Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.
Relapses are common in patients with drug-resistant urinary tract infections
Tue, 30 Oct 2018 14:59:08 -0500
Patients with a certain drug-resistant urinary tract infection were more likely to have a relapse of their infection within a week than those with non-resistant infections and were more likely to be prescribed an incorrect antibiotic according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
The Lancet Infectious Diseases journal publishes clinical trial results for Shionogi’s cefiderocol
Fri, 26 Oct 2018 00:33:52 -0500
Shionogi & Co., Ltd. announced today that The Lancet Infectious Diseases journal has published clinical results from the pivotal randomized controlled trial evaluating cefiderocol for the treatment of complicated urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections.
Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
Mon, 22 Oct 2018 04:19:43 -0500
Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.
Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
Mon, 22 Oct 2018 03:52:22 -0500
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
Mon, 22 Oct 2018 02:55:37 -0500
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease
Sat, 20 Oct 2018 21:28:24 -0500
While it is widely shown that possessing the ApoE4 gene is the major genetic risk factor of Alzheimer's disease, not all ApoE4 carriers develop AD.
Simple, inexpensive test quickly detects antibiotic-resistant 'superbugs'
Tue, 16 Oct 2018 10:12:38 -0500
When you get sick, you want the right treatment fast. But certain infectious microbes are experts at evading the very anti-bacterial drugs designed to fight them.
Spurred by convenience, millennials often spurn the ‘family doctor’ model
Tue, 09 Oct 2018 07:40:54 -0500
Calvin Brown doesn’t have a primary care doctor — and the peripatetic 23-year-old doesn’t want one.
Women who drink more water experience fewer bladder infections, study finds
Mon, 01 Oct 2018 23:23:43 -0500
In the controlled trial, women who drank an additional 1.5 liters of water daily experienced 48 percent fewer repeat bladder infections than those who drank their usual volume of fluids, said senior author Dr. Yair Lotan, Professor of Urology and with the Simmons Cancer Center at UT Southwestern.

rssfeedwidget.com